Authorized purpose: MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Clinical role
Screening mammography review or breast-density analysis as an adjunct to qualified physician interpretation.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Compatible acquisition system, image quality, breast view, population, display, and physician-review requirements are release-specific. MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Supported digital mammography or breast-tomosynthesis image data from compatible systems.
Who uses it?Intended users: Qualified mammography technologists and interpreting physicians.
What does the software produce?Output: Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.
What is its most important limitation?Key limitation: Compatible acquisition system, image quality, breast view, population, display, and physician-review requirements are release-specific. MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Clinical takeaway. Clinical role: MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone testing on FFDM from Hologic and GE devices, with mammogram-level ROC AUC 0.883 (0.873, 0.892) combined, and a retrospective multi reader multi case study of 240 mammographic screening images from a US center, read by 14 radiologists with and without the device, with cancer status verified by biopsy or follow-up. Average reader AUC went from 0.77 to 0.8 (difference = 0.028; P = 0.035). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Compatible acquisition system, image quality, breast view, population, display, and physician-review requirements are release-specific. MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
The exact FDA document reports standalone testing on FFDM from Hologic and GE devices, with mammogram-level ROC AUC 0.883 (0.873, 0.892) combined, and a retrospective multi reader multi case study of 240 mammographic screening images from a US center, read by 14 radiologists with and without the device, with cancer status verified by biopsy or follow-up. Average reader AUC went from 0.77 to 0.8 (difference = 0.028; P = 0.035). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Mammogram level Standalone performance of the MammoScreen-AI algorithm in characterizing positive and negative US FFDM acquired on Hologic® devices, and performance comparison with FFDM acquired on GE® devices, are given in the table below:" … "Hologic® GE® Combined FOMGE-FOMHOL ROC 0.868 (0.851, 0.885) 0.887 (0.875, 0.898) 0.883 (0.873, 0.892) 0.018 (-0.002, 0.039) AUC". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports standalone testing on FFDM from Hologic and GE devices, with mammogram-level ROC AUC 0.883 (0.873, 0.892) combined, and a retrospective multi reader multi case study of 240 mammographic screening images from a US center, read by 14 radiologists with and without the device, with cancer status verified by biopsy or follow-up. Average reader AUC went from 0.77 to 0.8 (difference = 0.028; P = 0.035). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Mammogram level Standalone performance of the MammoScreen-AI algorithm in characterizing positive and negative US FFDM acquired on Hologic® devices, and performance comparison with FFDM acquired on GE® devices, are given in the table below:" … "Hologic® GE® Combined FOMGE-FOMHOL ROC 0.868 (0.851, 0.885) 0.887 (0.875, 0.898) 0.883 (0.873, 0.892) 0.018 (-0.002, 0.039) AUC". Read from the exact FDA decision document on 2026-11-14.
Standalone mammogram-level sensitivity for characterizing positive versus negative FFDM: 0.847 (0.829, 0.864) Hologic and GE combined; 0.844 (0.815, 0.872) Hologic; 0.849 (0.827, 0.871) GE. Intervals as reported.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Mammogram level Standalone performance of the MammoScreen-AI algorithm in characterizing positive and negative US FFDM acquired on Hologic® devices, and performance comparison with FFDM acquired on GE® devices, are given in the table below:" … "Hologic® GE® Combined FOMGE-FOMHOL ROC 0.868 (0.851, 0.885) 0.887 (0.875, 0.898) 0.883 (0.873, 0.892)". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone mammogram-level specificity for characterizing positive versus negative FFDM: 0.729 (0.721, 0.737) Hologic and GE combined; 0.705 (0.689, 0.722) Hologic; 0.738 (0.728, 0.747) GE. Intervals as reported.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Mammogram level Standalone performance of the MammoScreen-AI algorithm in characterizing positive and negative US FFDM acquired on Hologic® devices, and performance comparison with FFDM acquired on GE® devices, are given in the table below:" … "Hologic® GE® Combined FOMGE-FOMHOL ROC 0.868 (0.851, 0.885) 0.887 (0.875, 0.898) 0.883 (0.873, 0.892)". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K192854
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K192854.
PopulationThe labeled population and test materials for exact submission K192854; a general clinical study population is not established here.
Scopeexact submission
Tested versionMammoScreen (K192854)
IndependenceSponsor or vendor study
K192854
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
3 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported digital mammography or breast-tomosynthesis image data from compatible systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes MammoScreen as configured as a DICOM Web compliant node in a network that receives its input images from another DICOM node. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "MammoScreen is configured as a DICOM Web compliant node in a network and receives its input images from another DICOM node". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes MammoScreen as consisting of a processing server and a web interface, with its output displayed on the screen of a personal computer meeting User Manual requirements. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The product consists of a processing server and a web interface." … "The MammoScreen output will be displayed on the screen of a personal computer compliant with requirements specified in the User Manual.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes MammoScreen as consisting of a processing server and a web interface, with its output displayed on the screen of a personal computer meeting User Manual requirements. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The product consists of a processing server and a web interface." … "The MammoScreen output will be displayed on the screen of a personal computer compliant with requirements specified in the User Manual.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes MammoScreen as configured as a DICOM Web compliant node in a network that receives its input images from another DICOM node. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "MammoScreen is configured as a DICOM Web compliant node in a network and receives its input images from another DICOM node". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Current vendor material is product-family context for K192854 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
15Source classes checked
1Screened PubMed leads
3Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 3 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 3 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.